Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II - Seite 2
Presentation Details:
Title: | NT219, a novel dual inhibitor of STAT3 and IRS1/2, demonstrates anti-tumor activity with and without cetuximab in pembrolizumab-resistant head and neck cancer PDX models |
Date: | June 22, 2020 |
Abstract: | https://www.abstractsonline.com/pp8/#!/9045/presentation/2911 |
Lesen Sie auch
About Kitov Pharma
Kitov Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is a clinical-stage company focusing on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create
successful long-lasting treatments for people with cancer. Kitov’s oncology pipeline includes NT-219 and CM-24. NT-219 is a small molecule targeting the novel cancer drug resistance pathways IRS1/2
and STAT3. Kitov is currently advancing NT-219 in combination with cetuximab as a third-line or second-line treatment option for the treatment of recurrent and metastatic squamous cell carcinoma of
head & neck cancer (SCCHN) as well as a single agent monotherapy treatment in patients with advanced solid tumors in a planned Phase 1/2 study. CM-24 is a monoclonal antibody blocking CEACAM1,
a novel immune checkpoint that supports tumor immune evasion and survival through multiple pathways. Kitov plans to advance CM-24 as a combination therapy with anti-PD1 checkpoint inhibitors in
selected cancer indications in a Phase 1 study followed by a Phase 2 for the treatment of non-small cell lung cancer NSCLC and pancreatic cancer. Kitov has entered into a clinical collaboration
agreement with Bristol Myers Squibb Company (BMY) for the planned Phase 1/2 clinical trials to evaluate the combination of CM-24 with the PD-1 inhibitor nivolumab (Opdivo). Kitov is also the owner
of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension which was approved by the FDA for marketing in the
U.S in May 2018, and is expected to be launched in the near future in the U.S. by Kitov's partner Coeptis Pharmaceuticals. Kitov has also partnered to commercialize Consensi in China and South
Korea. The company is headquartered in Tel Aviv, Israel. For more information, please visit http://www.kitovpharma.com.